ImmunityBio, Inc. IBRX CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s capex?
- ImmunityBio, Inc. (IBRX) reported capex of $1.78M in Q1 2026.
- How has ImmunityBio, Inc.'s capex changed year-over-year?
- ImmunityBio, Inc.'s capex increased by 58.4% year-over-year, from $1.12M to $1.78M.
- What is the long-term trend for ImmunityBio, Inc.'s capex?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s capex has grown at a -41.8% compound annual growth rate (CAGR), from $33.56M to $3.85M.
- What does capex mean?
- Cash spent on physical assets like buildings, machinery, or equipment.
- How do you interpret capex?
- High spending indicates investment in future capacity, while low spending may indicate a focus on asset-light operations or capital conservation.
- How does capex compare across companies?
- Biotech companies often have lower CapEx compared to manufacturing firms unless they are building internal production facilities.